Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-719 for prevention of acute kidney injury in surgery
NCT01897519Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of modimelanotide in acute kidney injury (AKI), sponsored by AbbVie Inc.. Started May 2013; status: terminated.
02
Drugs
modimelanotide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT01897519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897519.